Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 May 7;108(11):2940–2949. doi: 10.1210/clinem/dgad249

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Figure 2. — Primary and secondary outcomes. Endpoints up to 312 weeks after randomization are shown. The results of the combined primary endpoint show a significant superiority of canagliflozin compared with placebo (Panel A). Results on secondary endpoints show superiority of canagliflozin on improvement of ALT >30% (Panel B) and normalization of ALT (Panel C). Panel D shows weight loss achieved with canagliflozin compared with placebo at 1 year after randomization.